Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of BI 894416 in healthy Japanese males
jRCT2080225328Phase 1Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 894416 (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Safety and tolerability of BI 894416 and Pharmacokinetics of BI 894416. Started Aug 2020; status: suspended.
02
Drugs
BI 894416
Beyond the preview
Go deeper on jRCT2080225328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225328.